Tag Archives: Keay Nakae

ProQR (PRQR) Receives a Buy from Chardan Capital

In a report released today, Keay Nakae from Chardan Capital reiterated a Buy rating on ProQR (PRQR – Research Report), with a price target of $25.00. The company’s shares closed last Monday at $6.07, close to its 52-week low of

Chardan Capital Remains a Buy on Dicerna Pharma (DRNA)

In a report released today, Keay Nakae from Chardan Capital reiterated a Buy rating on Dicerna Pharma (DRNA – Research Report), with a price target of $18. The company’s shares closed last Monday at $14.12. According to TipRanks.com, Nakae has

Chardan Capital Reiterates a Buy Rating on Arbutus Biopharma Corporation (ABUS)

In a report released today, Keay Nakae from Chardan Capital reiterated a Buy rating on Arbutus Biopharma Corporation (ABUS – Research Report), with a price target of $5. The company’s shares closed yesterday at $2.34, close to its 52-week low

Chardan Capital Reiterates a Buy Rating on OncoCyte Corp (OCX)

In a report released today, Keay Nakae from Chardan Capital reiterated a Buy rating on OncoCyte Corp (OCX – Research Report), with a price target of $7.75. The company’s shares closed yesterday at $5.08. According to TipRanks.com, Nakae is ranked

Kamada (KMDA) Receives a Buy from Chardan Capital

Chardan Capital analyst Keay Nakae reiterated a Buy rating on Kamada (KMDA – Research Report) today and set a price target of $7. The company’s shares closed yesterday at $5.73. According to TipRanks.com, Nakae ‘s ranking currently consits of no

Chardan Capital Thinks ContraFect’s Stock is Going to Recover

Chardan Capital analyst Keay Nakae reiterated a Buy rating on ContraFect (CFRX – Research Report) today and set a price target of $1.50. The company’s shares closed yesterday at $0.51, close to its 52-week low of $0.36. Nakae commented: “We